PHASE I AND PHASE II CLINICAL STUDIES WITH LHRH ANTAGONIST

LHRH 拮抗剂的 I 期和 II 期临床研究

• 批准号: 3865096
• 负责人: RONALD S SWERDLOFF
• 金额: --
• 依托单位: LOS ANGELES COUNTY HARBOR-UCLA MED CTR
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3865096
• 关键词: clinical trials; family planning; follicle stimulating hormone; human subject; human therapy evaluation; inhibitor /antagonist; injection /infusion; luteinizing hormone; male; spermatogenesis inhibitor; testosterone

To establish dose response and duration of action on LH, FSH and testosterone levels after a single subcutaneous injection. The effect of 3 dose levels of LHRH antagonist given either intermittently or continuously will be studied to establish the minimal effective dose for LH and FSH suppression. To evaluate the combination of LH suppression and testosterone replacement as a method of male contraception.

确定 LH、FSH 和 LH 的剂量反应和作用持续时间 单次皮下注射后的睾酮水平。 这 3 个剂量水平的 LHRH 拮抗剂的作用 将间歇性或连续性地进行研究，以确定 抑制 LH 和 FSH 的最小有效剂量。 评估 LH 抑制和睾酮替代相结合作为 男性避孕方法。